| Pirtobrutinib studied in …STUDIED_INderived52 of 52show fewer |
|---|
| → studied in | NCT06252675Phase 2 · recruiting Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma · 52 trials list this drug (46 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06973187Phase 3 · recruiting A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma · 52 trials list this drug (46 active) | — | — | Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07685717Phase 2 · recruiting Pirtobrutinib for the Treatment of Elderly Patients With Chronic Lymphocytic Leukemia · 52 trials list this drug (46 active) | — | — | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05023980Phase 3 · active not recruiting A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) · 52 trials list this drug (46 active) | — | — | Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07548450Phase 2 · not yet recruiting Mosunetuzumab in Combination With Pirtobrutinib in Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia (MPOWER) · 52 trials list this drug (46 active) | — | — | Waldenstrom Macroglobulinemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04662255Phase 3 · active not recruiting Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL) · 52 trials list this drug (46 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06553872Phase 2 · recruiting Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL · 52 trials list this drug (46 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07218341Phase 4 · recruiting A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma · 52 trials list this drug (46 active) | — | — | Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07831395Phase 2 · not yet recruiting Rituximab, Pirtobrutinib, Lisaftoclax and Liposomal Mitoxantrone for for Richter Syndrome Transformed From CLL · 52 trials list this drug (46 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04623541Phase 1/Phase 2 · active not recruiting Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome · 52 trials list this drug (46 active) | — | — | Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06812715Phase 2 · recruiting Clonal Dynamics of Chronic Lymphocytic Leukaemia Treated With Pirtobrutinib After Previous Treatment With Zanubrutinib · 52 trials list this drug (46 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07516093Phase 3 · recruiting Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL · 52 trials list this drug (46 active) | — | — | B-Cell Malignant Neoplasm,Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07784101Phase 3 · not yet recruiting A Phase 3 Study to Compare the Efficacy of ICP-248 in Combination With Orelabrutinib Versus Pirtobrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL). · 52 trials list this drug (46 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07428707early Phase 1 · recruiting Immune Profiling of CLL/SLL Treated With First-Line Pirtobrutinib · 52 trials list this drug (46 active) | — | — | Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05254743Phase 3 · recruiting A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) · 52 trials list this drug (46 active) | — | — | Leukemia,Lymphoid Leukemia,Chronic Lymphocytic Leukemia+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07342478Phase 3 · recruiting ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL · 52 trials list this drug (46 active) | — | — | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma,Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05990465Phase 1 · recruiting LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies · 52 trials list this drug (46 active) | — | — | Non-Hodgkin Lymphoma,Burkitt Lymphoma,Diffuse Large B-Cell Lymphoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06967610Phase 2 · recruiting Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL). · 52 trials list this drug (46 active) | — | — | Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05024045Phase 1 · completed Study of Oral LOXO-338 in Patients With Advanced Blood Cancers · 52 trials list this drug (46 active) | — | — | B-Cell Malignant Neoplasm,Leukemia,Lymphoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07684950Phase 2 · not yet recruiting Lisaftoclax Plus Pirtobrutinib in Relapsed or Refractory Mantle Cell Lymphoma After BTK-Targeted Therapy · 52 trials list this drug (46 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06522386Phase 2 · active not recruiting GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell Lymphoma · 52 trials list this drug (46 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07231952Phase 2 · recruiting A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL) · 52 trials list this drug (46 active) | — | — | Lymphoplasmacytic Lymphoma,Waldenstrom Macroglobulinemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07220187Phase 3 · not yet recruiting Adding Pirtobrutinib to the Usual Treatment for People With Newly Diagnosed Richter Transformation, The PIRAMID Trial · 52 trials list this drug (46 active) | — | — | Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma,Transformed Small Lymphocytic Lymphoma to Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06948786Phase 2 · recruiting Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial · 52 trials list this drug (46 active) | — | — | Follicular Lymphoma,Grade 1 Follicular Lymphoma,Grade 2 Follicular Lymphoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07622784Phase 2 · not yet recruiting Pirtobrutinib Maintenance After CAR-T Therapy in Relapsed or Refractory B-Cell Lymphoma · 52 trials list this drug (46 active) | — | — | B-Cell Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07624799Phase 2 · not yet recruiting Fixed Duration Treatment With Combined Pirtobrutinib and Short Course Immuno-chemotherapy in Fit Patients With Previously Untreated Symptomatic Chronic Lymphocytic Leukemia (CLL). · 52 trials list this drug (46 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05734495Phase 2 · active not recruiting Pirtobrutinib and Venetoclax in Waldenström Macroglobulinemia · 52 trials list this drug (46 active) | — | — | Waldenstrom Macroglobulinemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06588478Phase 2 · recruiting A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma · 52 trials list this drug (46 active) | — | — | Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05529069Phase 2 · recruiting Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients · 52 trials list this drug (46 active) | — | — | Hematopoietic and Lymphoid Cell Neoplasm,Non-Hodgkin Lymphoma,Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05536349Phase 2 · recruiting Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT) · 52 trials list this drug (46 active) | — | — | Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04666038Phase 3 · active not recruiting Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) · 52 trials list this drug (46 active) | — | — | Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06263491Phase 2 · recruiting Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients · 52 trials list this drug (46 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07162181Phase 2 · active not recruiting Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers · 52 trials list this drug (46 active) | — | — | B-Cell Malignant Neoplasm,Leukemia,Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07525817not yet recruiting A Real-World Study of Pirtobrutinib in cBTKi-Resistant/Intolerant Mature B-Cell Lymphoma · 52 trials list this drug (46 active) | — | — | Mature B-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06876649Phase 4 · recruiting A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib · 52 trials list this drug (46 active) | — | — | Non-Hodgkin Lymphoma,Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06876662Phase 4 · recruiting A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma · 52 trials list this drug (46 active) | — | — | Non-Hodgkin Lymphoma,Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06466122Phase 2 · recruiting Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients With CLL or SLL Resistant to Covalent BTKi · 52 trials list this drug (46 active) | — | — | Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05677919Phase 2 · active not recruiting Pirtobrutinib and Venetoclax With MRD Detection for Previously Untreated Chronic Lymphocytic Leukemia · 52 trials list this drug (46 active) | — | — | Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04849416Phase 2 · completed A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia) · 52 trials list this drug (46 active) | — | — | B-Cell Malignant Neoplasm,Leukemia,Lymphoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04965493Phase 3 · active not recruiting A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) · 52 trials list this drug (46 active) | — | — | Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03740529Phase 1/Phase 2 · completed A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL · 52 trials list this drug (46 active) | — | — | B-Cell Malignant Neoplasm,Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06333262Phase 2 · recruiting Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia · 52 trials list this drug (46 active) | — | — | Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06043674Phase 2 · recruiting Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation · 52 trials list this drug (46 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05317936Phase 1/Phase 2 · terminated Pirtobrutinib (LOXO-305) Consolidation for MRD Eradication in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL) Treated With Venetoclax · 52 trials list this drug (46 active) | — | — | Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07052695Phase 1/Phase 2 · recruiting Mosunetuzumab for CLL MRD Clearance · 52 trials list this drug (46 active) | — | — | Leukemia,Lymphoma,Chronic Lymphocytic Leukemia+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06390956Phase 2 · recruiting Pirtobrutinib in Combination With Rituximab in Adults With Untreated Marginal Zone Lymphoma (PIONEER-MZL) · 52 trials list this drug (46 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07255963Phase 2 · recruiting Pirtobrutinib, Lisaftoclax, and Rituximab in the Treatment of R/R DLBCL · 52 trials list this drug (46 active) | — | — | Interdigitating Dendritic Cell Sarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07207785Phase 2 · not yet recruiting PirtobrUtinib as Frontline Therapy for Elderly Unfit/Frail Patient With MAntle Cell Lymphoma · 52 trials list this drug (46 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07122609Phase 2 · not yet recruiting Pirtobrutinib in Combination With Rituximab, Gemcitabine, Oxaliplatin With or Without Polatuzumab Vedotin in Covalent BTK Inhibitor-Pretreated Relapsed/Refractory Diffuse Large B-Cell Lymphoma · 52 trials list this drug (46 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06839872Phase 2 · withdrawn A Study to Investigate the Sequencing Strategy of Pirtobrutinib After Disease Progression on First-line Acalabrutinib Treatment for Adult Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma · 52 trials list this drug (46 active) | — | — | Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05172700approved for marketing Expanded Access Program for Pirtobrutinib for Participants With B-Cell Cancer · 52 trials list this drug (46 active) | — | — | Leukemia,Lymphoma,Mantle Cell Lymphoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05833763Phase 2 · recruiting A Phase 2 Trial of GlOfitamab anD pIrtobrutinib in Mantle Cell Lymphoma Patients With Prior BTK Inhibitor Exposure. · 52 trials list this drug (46 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |